Last edition
News about Global Pharma
AstraZeneca Announces Investment of USD 3.5 Billion in R&D in US
AstraZeneca’s expanding footprint in the US includes, a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and a specialty manufacturing in Texas.
Global Pharma | 14/11/2024 | By Aishwarya | 371
Vaxinano Signs Exclusive Licensing Deal for Canine Leishmaniasis Vaccine with Vetoquinol
Canine leishmaniasis is an incurable multisystemic zoonosis caused by a parasite that leads to death in symptomatic dogs, affecting globally 100 million dogs.
Global Pharma | 13/11/2024 | By Aishwarya | 687
Alembic Pharmaceuticals Bags USFDA Final Approval for Diltiazem Hydrochloride Capsules
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC.
Global Pharma | 12/11/2024 | By Aishwarya | 578
Lakeside Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical
The acquisition, valued at RMB 4.0 million (USD 0.6 million), is anticipated to deliver approximately USD 7 million of annual revenues to Lakeside.
Global Pharma | 12/11/2024 | By Aishwarya | 233
Alteogen Signs Exclusive License Deal with Daiichi Sankyo to Develop Subcutaneous ENHERTU
Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki).
Global Pharma | 11/11/2024 | By Aishwarya | 517
The scheme is a comprehensive scheme which targets critical areas of the medical device industry, covering manufacturing of key components and accessories, skill development, support for clinical studies, development of common infrastructure and industry promotion.
Global Pharma | 11/11/2024 | By Aishwarya | 277
Samsung Biologics Secures ISO Certifications for its Business Excellence
The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics' headquarters.
Global Pharma | 11/11/2024 | By Aishwarya | 660
Parallel Fluidics Secures USD 7 Million Seed Round to Boost Microfluidic Development
The funding will help drive the growth of the company's on-demand design and manufacturing platform, expand its hardware and software solutions, and commercialize its new product, MV-2.
Global Pharma | 08/11/2024 | By Aishwarya | 392
NJ Bio Partners with Charles River to Accelerate ADC Development
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
Global Pharma | 08/11/2024 | By Aishwarya | 316
Microbiologics Acquires SensID to Expand its Portfolio in Diagnostic Quality Controls
The combined expertise of Microbiologics and SensID will empower both companies to deliver a broader portfolio of quality control solutions to further support diagnostic technology developers and healthcare professionals and ultimately improve patient care worldwide.
Global Pharma | 07/11/2024 | By Aishwarya | 573
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy